BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 29845424)

  • 1. The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells.
    Kiweler N; Brill B; Wirth M; Breuksch I; Laguna T; Dietrich C; Strand S; Schneider G; Groner B; Butter F; Heinzel T; Brenner W; Krämer OH
    Arch Toxicol; 2018 Jul; 92(7):2227-2243. PubMed ID: 29845424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.
    Stubbs MC; Kim W; Bariteau M; Davis T; Vempati S; Minehart J; Witkin M; Qi J; Krivtsov AV; Bradner JE; Kung AL; Armstrong SA
    Clin Cancer Res; 2015 May; 21(10):2348-58. PubMed ID: 25688158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer.
    Aghdassi A; Sendler M; Guenther A; Mayerle J; Behn CO; Heidecke CD; Friess H; Büchler M; Evert M; Lerch MM; Weiss FU
    Gut; 2012 Mar; 61(3):439-48. PubMed ID: 22147512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.
    Park KC; Heo JH; Jeon JY; Choi HJ; Jo AR; Kim SW; Kwon HJ; Hong SJ; Han KS
    BMC Cancer; 2015 Jan; 15():19. PubMed ID: 25613585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis.
    Jurkin J; Zupkovitz G; Lagger S; Grausenburger R; Hagelkruys A; Kenner L; Seiser C
    Cell Cycle; 2011 Feb; 10(3):406-12. PubMed ID: 21270520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDAC1 and HDAC2 collectively regulate intestinal stem cell homeostasis.
    Zimberlin CD; Lancini C; Sno R; Rosekrans SL; McLean CM; Vlaming H; van den Brink GR; Bots M; Medema JP; Dannenberg JH
    FASEB J; 2015 May; 29(5):2070-80. PubMed ID: 25648995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Class I Histone Deacetylases 1 and 2 Promotes Urothelial Carcinoma Cell Death by Various Mechanisms.
    Pinkerneil M; Hoffmann MJ; Deenen R; Köhrer K; Arent T; Schulz WA; Niegisch G
    Mol Cancer Ther; 2016 Feb; 15(2):299-312. PubMed ID: 26772204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex.
    von Burstin J; Eser S; Paul MC; Seidler B; Brandl M; Messer M; von Werder A; Schmidt A; Mages J; Pagel P; Schnieke A; Schmid RM; Schneider G; Saur D
    Gastroenterology; 2009 Jul; 137(1):361-71, 371.e1-5. PubMed ID: 19362090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term stimulation with histone deacetylase inhibitor trichostatin a induces epithelial-mesenchymal transition in nasopharyngeal carcinoma cells without increasing cell invasion ability.
    Shen Z; Liao X; Shao Z; Feng M; Yuan J; Wang S; Gan S; Ha Y; He Z; Jie W
    BMC Cancer; 2019 Mar; 19(1):262. PubMed ID: 30902084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, Synthesis and Biological Evaluation of New HDAC1 and HDAC2 Inhibitors Endowed with Ligustrazine as a Novel Cap Moiety.
    Al-Sanea MM; Gotina L; Mohamed MF; Grace Thomas Parambi D; Gomaa HAM; Mathew B; Youssif BGM; Alharbi KS; Elsayed ZM; Abdelgawad MA; Eldehna WM
    Drug Des Devel Ther; 2020; 14():497-508. PubMed ID: 32103894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
    Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
    PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase 1 is required for transforming growth factor-beta1-induced epithelial-mesenchymal transition.
    Lei W; Zhang K; Pan X; Hu Y; Wang D; Yuan X; Shu G; Song J
    Int J Biochem Cell Biol; 2010 Sep; 42(9):1489-97. PubMed ID: 20580679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HDAC inhibition activates the apoptosome via Apaf1 upregulation in hepatocellular carcinoma.
    Buurman R; Sandbothe M; Schlegelberger B; Skawran B
    Eur J Med Res; 2016 Jun; 21(1):26. PubMed ID: 27342975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HDAC1-induced epigenetic silencing of ASPP2 promotes cell motility, tumour growth and drug resistance in renal cell carcinoma.
    Li H; Wang X; Zhang C; Cheng Y; Yu M; Zhao K; Ge W; Cai A; Zhang Y; Han F; Hu Y
    Cancer Lett; 2018 Sep; 432():121-131. PubMed ID: 29890207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitors inhibit lung adenocarcinoma metastasis via HDAC2/YY1 mediated downregulation of Cdh1.
    Wang D; Yang Y; Cao Y; Meng M; Wang X; Zhang Z; Fu W; Duan S; Tang L
    Sci Rep; 2023 Jul; 13(1):12069. PubMed ID: 37495623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of Histone Deacetylase Inhibitor Sensitivity in Combination with Cyclin-Dependent Kinase Inhibition for the Treatment of Oral Squamous Cell Carcinoma.
    Zhao B; Huang Z; Qin Z; Li Y; Wang T; Wang L; Zhou W; Yu C; Wang X; Yang S; Fan Y; Xiang R
    Cell Physiol Biochem; 2019; 53(1):141-156. PubMed ID: 31237760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
    Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
    Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the Effects of Valproic Acid Treatment on Cell Survival and Epithelial-Mesenchymal Transition-Related Features of Human Gastric Cancer Cells.
    Jahani M; Khanahmad H; Nikpour P
    J Gastrointest Cancer; 2021 Jun; 52(2):676-681. PubMed ID: 32621111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitors dysregulate DNA repair proteins and antagonize metastasis-associated processes.
    Kiweler N; Wünsch D; Wirth M; Mahendrarajah N; Schneider G; Stauber RH; Brenner W; Butter F; Krämer OH
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):343-356. PubMed ID: 31932908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Troglitazone inhibits histone deacetylase activity in breast cancer cells.
    Davies GF; Ross AR; Arnason TG; Juurlink BH; Harkness TA
    Cancer Lett; 2010 Feb; 288(2):236-50. PubMed ID: 19699029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.